What should we measure in the diabetic patient and how does this respond to therapy?
作者信息
Johnston Desmond G, Robinson Stephen, Forbes Shareen
机构信息
Endocrinology and Metabolic Medicine, Faculty of Medicine, Imperial College, St Mary's Hospital, London W2 1NY.
出版信息
Br J Clin Pharmacol. 2002 Jul;54(1):81-6. doi: 10.1046/j.1365-2125.2002.01624.x.
Abstract
摘要
相似文献
1
What should we measure in the diabetic patient and how does this respond to therapy?我们应该测量糖尿病患者的哪些指标，以及这些指标对治疗的反应如何？
Br J Clin Pharmacol. 2002 Jul;54(1):81-6. doi: 10.1046/j.1365-2125.2002.01624.x.
2
Diabetes mellitus: the role of the laboratory--an update.糖尿病：实验室检查的作用——最新进展
J Pak Med Assoc. 2002 Dec;52(12):569-75.
3
[Glucose intolerance -- diabetes].[葡萄糖耐量异常——糖尿病]
Nihon Rinsho. 2008 Sep;66(9):1753-60.
4
Tests of glycemia in diabetes.糖尿病血糖检测
Diabetes Care. 1995 Jun;18(6):896-909. doi: 10.2337/diacare.18.6.896.
5
Tests of glycemia in diabetes.糖尿病患者的血糖检测
Diabetes Care. 2000 Jan;23 Suppl 1:S80-2.
6
[Screening of glucose intolerance with fasting blood samples].[采用空腹血样筛查葡萄糖耐量异常]
Nihon Rinsho. 1997 Nov;55 Suppl:904-9.
7
[Combined use of fasting plasma glucose and HbA1c (as a screening test)].[空腹血糖与糖化血红蛋白联合检测（作为筛查试验）]
Nihon Rinsho. 2005 Feb;63 Suppl 2:390-3.
8
[Blood sugar monitoring].[血糖监测]
Soins. 1989 May(524):15-21.
9
Monitoring glycemia in diabetes. Short-term assessment.糖尿病患者血糖监测。短期评估。
Endocrinol Metab Clin North Am. 1997 Sep;26(3):475-86. doi: 10.1016/s0889-8529(05)70261-9.
10
Measuring the transition to diabetes.测量向糖尿病的转变。
J Diabetes Complications. 2013 Mar-Apr;27(2):101-2. doi: 10.1016/j.jdiacomp.2012.10.002. Epub 2012 Nov 17.
本文引用的文献
1
Diabetic nephropathy: pathogenesis, diagnosis, and prevention of progression.糖尿病肾病：发病机制、诊断及疾病进展的预防
Adv Intern Med. 2001;46:359-408.
2
Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of european prospective investigation of cancer and nutrition (EPIC-Norfolk).欧洲癌症与营养前瞻性调查（EPIC - 诺福克）诺福克队列男性中的糖化血红蛋白、糖尿病与死亡率
BMJ. 2001 Jan 6;322(7277):15-8. doi: 10.1136/bmj.322.7277.15.
3
Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project.普伐他汀对由冠心病危险因素定义的亚组中冠心病事件的影响：普伐他汀前瞻性汇总项目
Circulation. 2000 Oct 17;102(16):1893-900. doi: 10.1161/01.cir.102.16.1893.
4
Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study.血糖水平与2型糖尿病大血管及微血管并发症的关联（英国前瞻性糖尿病研究35）：前瞻性观察研究
BMJ. 2000 Aug 12;321(7258):405-12. doi: 10.1136/bmj.321.7258.405.
5
Plasma glucose and prediction of microvascular disease and mortality: evaluation of 1997 American Diabetes Association and 1999 World Health Organization criteria for diagnosis of diabetes.血浆葡萄糖与微血管疾病及死亡率的预测：对1997年美国糖尿病协会和1999年世界卫生组织糖尿病诊断标准的评估
Diabetes Care. 2000 Aug;23(8):1113-8. doi: 10.2337/diacare.23.8.1113.
6
LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study.在伴有胰岛素抵抗且低密度脂蛋白（LDL）水平较低的糖尿病个体中，LDL胆固醇是冠心病的有力预测指标：强心研究。
Arterioscler Thromb Vasc Biol. 2000 Mar;20(3):830-5. doi: 10.1161/01.atv.20.3.830.
7
Standardization of HbA1c measurements--a consensus statement.糖化血红蛋白（HbA1c）测量的标准化——共识声明
Diabet Med. 2000 Jan;17(1):5-6. doi: 10.1046/j.1464-5491.2000.00228.x.
8
Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators.雷米普利对糖尿病患者心血管和微血管结局的影响：HOPE研究及MICRO-HOPE子研究结果。心脏结局预防评估研究组。
Lancet. 2000 Jan 22;355(9200):253-9.
9
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.磺脲类或胰岛素强化血糖控制与传统治疗及2型糖尿病患者并发症风险的比较（英国前瞻性糖尿病研究[UKPDS 33]）。英国前瞻性糖尿病研究（UKPDS）小组
Lancet. 1998 Sep 12;352(9131):837-53.
Zotero 插件